These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1405603)

  • 21. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    Yoshizawa H; Chang AE; Shu S
    J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer.
    Li Q; Iuchi T; Jure-Kunkel MN; Chang AE
    Int J Biol Sci; 2007 Nov; 3(7):455-62. PubMed ID: 18071585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of in vitro sensitized cells generated by in vivo priming with OK-432 for adoptive immunotherapy of the poorly immunogenic B16-Bl6 melanoma.
    Mukai S; Kato H; Kimura S; Asai K; Kawahito Y; Inoue M; Yamamura Y; Sano H; Sugino S; Shu S; Kondo M
    Int J Immunopharmacol; 1996 Feb; 18(2):141-53. PubMed ID: 8799364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
    Shu S; Sussman JJ; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy.
    Sondak VK; Wagner PD; Shu S; Chang AE
    Arch Surg; 1991 Apr; 126(4):442-6. PubMed ID: 2009059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic efficacy of Th1 and Th2 L-selectin--CD4+ tumor-reactive T cells.
    To WC; Seeley BM; Barthel SW; Shu S
    Laryngoscope; 2000 Oct; 110(10 Pt 1):1648-54. PubMed ID: 11037819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
    Yang SC; Fry KD; Grimm EA; Roth JA
    Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
    Marincola FM; Ettinghausen S; Cohen PA; Cheshire LB; Restifo NP; Mulé JJ; Rosenberg SA
    J Immunol; 1994 Apr; 152(7):3500-13. PubMed ID: 8144931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Purification of L-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes.
    Kagamu H; Shu S
    J Immunol; 1998 Apr; 160(7):3444-52. PubMed ID: 9531305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor.
    Kato K; Tanabe T; Agatsuma T; Suzuki S; Nitanai H; Hashimoto Y
    Jpn J Cancer Res; 1991 Apr; 82(4):464-9. PubMed ID: 1904426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
    Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity.
    Arora A; Su G; Mathiowitz E; Reineke J; Chang AE; Sabel MS
    J Surg Oncol; 2006 Oct; 94(5):403-12. PubMed ID: 16967445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.